⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
6,299
Total Claims
$3.7M
Drug Cost
767
Beneficiaries
$4,798
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+22%
Cost per patient vs peers
$4,798 vs $3,933 avg
+15%
Brand preference vs peers
58.6% vs 51.2% avg
Brand vs Generic
41% generic
Brand: 3,343 claims · $3.5M
Generic: 2,357 claims · $94K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 290 | $481K |
| Insulin Glargine,hum.Rec.Anlog | 443 | $338K |
| Semaglutide | 175 | $311K |
| Insulin Lispro | 197 | $292K |
| Sitagliptin Phosphate | 244 | $271K |
| Empagliflozin | 186 | $243K |
| Insulin Aspart | 136 | $240K |
| Tirzepatide | 119 | $200K |
| Insulin Regular, Human | 45 | $147K |
| Insulin Degludec | 120 | $120K |
| Insulin Glargine,hum.Rec.Anlog | 101 | $108K |
| Dapagliflozin Propanediol | 72 | $102K |
| Empagliflozin/Metformin Hcl | 50 | $76K |
| Semaglutide | 36 | $57K |
| Insulin Aspart | 30 | $46K |
Prescribing Profile
Patient Profile
69
Avg Age
64%
Female
1.81
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About